GLP1 lawsuits.

The FDA is not a gate keeper, but a captive of the drug producers.

The Numbers at a Glance

What started as a trickle of individual lawsuits has exploded into one of the largest pharmaceutical mass torts in the country. We’re now looking at over 4,700 cases in the GI injury MDL alone, with the newer vision-loss MDL growing rapidly.

MDLInjuriesCase CountStatusMDL 3094Gastroparesis, ileus, bowel obstruction, severe GI complications4,700+Active discovery; Daubert hearings set for Sept 2026MDL 3163NAION (sudden, often permanent vision loss)~86+ federal casesEstablished Dec 2025; early stages

Both MDLs are consolidated before Judge Karen S. Marston in the Eastern District of Pennsylvania. The defendants are Novo Nordisk (Ozempic, Wegovy, Rybelsus, Saxenda) and Eli Lilly (Mounjaro, Zepbound, Trulicity).

---

🔥 The Core Allegations

The plaintiffs’ theory is straightforward and damning — and it mirrors the playbook we’ve seen with countless other blockbuster drugs:

The manufacturers knew, or should have known, that these drugs could cause severe, persistent, and sometimes permanent injuries, but they deliberately downplayed the risks to protect a cash cow.

Specifically, the lawsuits allege:

• Failure to Warn: Labels described delayed gastric emptying as a benign “mechanism of action” — a minor slowing in the early postprandial phase. What patients actually experienced was full-blown gastroparesis — stomach paralysis causing violent cyclical vomiting, hospitalization, teeth falling out from acid erosion, and inability to digest food for days. The labels never warned this could happen.

• Fraudulent Marketing: The companies marketed these drugs as safe, well-tolerated solutions while knowing the GI adverse event data from clinical trials and post-marketing reports painted a very different picture.

• Design Defect: The very mechanism that makes these drugs “work” — delaying gastric emptying — is also what causes the catastrophic injuries when that delay becomes pathological and persistent.

The MDL master complaint spells out an exhaustive list of injuries: gastroparesis requiring hospitalization, refractory gastroparesis leading to Wernicke’s encephalopathy, ileus, intestinal obstruction, ischemic bowel, gallbladder removal, DVT, pulmonary embolism, esophageal tearing, muscle wasting, and severe micronutrient deficiencies.

---

⚖️ Where Things Stand Procedurally

The GI MDL (3094)

This is the main event. As of late April 2026, the case is barreling toward the critical Daubert phase — the battle over expert testimony that will effectively determine whether these cases live or die:

• May 19, 2026: Deadline for Daubert motions and summary judgment motions (initial briefs)

• June 17, 2026: Opposition briefs to Daubert motions due

• June 30, 2026: Opposition briefs to summary judgment due

• July 15, 2026: Reply briefs supporting Daubert motions

• August 7, 2026: Reply briefs supporting summary judgment

• September 10-18, 2026: Live Daubert hearings in Courtroom 16B — this is where Judge Marston will grill the experts and decide what science the jury gets to hear

No bellwether trial date has been set yet, but realistically we’re looking at late 2026 or early 2027 for the first test cases to reach a jury.

The Vision Loss MDL (3163)

This is the newer, rapidly expanding front. The JPML established MDL 3163 in December 2025 specifically for NAION — non-arteritic anterior ischemic optic neuropathy, a form of sudden, painless, and often irreversible vision loss caused by reduced blood flow to the optic nerve. Studies published in 2024 identified the association, and lawsuits started piling up immediately. These cases are in much earlier stages than the GI cases.

---

🧪 The Gastric Emptying Study Ruling

A pivotal moment came in August 2025 when Judge Marston ruled that plaintiffs claiming gastroparesis must have a gastric emptying study (GES) in their medical records to support the diagnosis. This was a double-edged sword:

• Narrowed the pool — cases relying solely on symptom reports without objective GES documentation got filtered out

• Strengthened the survivors — the cases that remain have hard, objective diagnostic evidence, making them harder for the defense to dismiss as subjective complaints

For patients with ileus or bowel obstruction claims, GES documentation isn’t necessarily required — CT imaging, hospital records, and surgical documentation can establish those injuries independently.

---

🏭 The FDA’s Slow-Walked Response

The regulatory timeline tells its own story about how these risks were handled:

• Original labels: Described delayed gastric emptying as a minor mechanism of action. No gastroparesis warning anywhere.

• September 2023: FDA finally added ileus warnings to Ozempic — only after lawsuits and media coverage forced the issue.

• January 2025: “Severe gastrointestinal adverse reactions” warning added.

• October 2025: Label updated to say Ozempic is “not recommended in patients with severe gastroparesis” — still framing gastroparesis as a pre-existing condition to watch for, not as something the drug causes.

Notice the pattern: the label updates consistently lag behind the injury reports and litigation by years. The FDA’s revolving-door relationship with pharma means these warnings arrive only after the damage is done and the legal exposure becomes undeniable.

---

💰 No Settlements Yet — But the Pressure Is Building

As of May 2026, zero global settlements have been announced in either MDL. Novo Nordisk and Eli Lilly are fighting hard — they’ve raised preemption defenses (arguing FDA-approved labeling preempts state failure-to-warn claims), challenged causation, and pushed for strict diagnostic requirements.

But the math is getting ugly for them. With over 4,700 cases and hundreds more filing monthly, the potential liability runs into the billions. The bellwether trials — whenever they arrive — will be the real test. If juries start awarding substantial verdicts, expect the settlement floodgates to open. The classic pharma playbook: deny, delay, then write a giant check with no admission of wrongdoing.

Meanwhile, the FDA has also moved against compounding pharmacies and telehealth providers mass-marketing “unapproved” versions of these drugs — adding another layer of regulatory and legal chaos.

---

🩺 The Iatrogenic Big Picture

This is a textbook case of what happens when a drug class gets pushed as a near-miraculous solution — massive direct-to-consumer advertising, celebrity endorsements, off-label prescribing for weight loss, and a cultural frenzy — while the true risk profile only emerges years later through litigation and independent investigation.

The GLP-1 story is still being written, but the early chapters follow a depressingly familiar script: blockbuster profits first, patient safety second, and accountability only when forced by the courts.